LONDON, March 19 /PRNewswire/ -- The 2009 Frost & Sullivan European Drug Discovery Product Innovation Award is presented to Xenometrix AG in recognition of its active role in the production of single and multiple endpoint cytotoxicity assays.
These test kits, used in the early screening stages of drug discovery, improve the effectiveness of drug discovery and development through lead optimisation. One product line - the IN CYTOTOX PAN I kit - enables researchers to detect 4 main toxicity parameters on a single sample; a feat unmatched by competing life science organisations.
"The multiple endpoint IN CYTOTOX test kits are able to determine up to four metabolic parameters from the same cellular sample," explains Frost & Sullivan Research Analyst Dr. Laleh Safinia. "The kit eases some of the bottlenecks in preclinical drug discovery and development and increases the relevance of correlation of the tests, reduces the overall handling time, volume of test compounds needed, plastic waste and consequently, the cost."
The PAN I cytotoxicity kit allows the application of 4 commonly used cytotoxicity assays sequentially on a cellular sample. Such an approach enhances the probability of identifying toxic compounds, reduces consumption of valuable primary cells, uses lower test compounds than with individual assays and removes inter-assay variability due to differences in cell composition, cellular activity and cell density.
"Xenometrix offers testing of chemicals for cytotoxic effects using a range of assays and assay combinations sold as test kits," states Safinia. "The cytotoxicity kits are used by major pharmaceutical, chemical and cosmetic industries, contract service labs as well as authorities analysing environmental toxicants." <
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved